Chai Discovery nabs $400M Series C as AI-designed antibodies reach Big Pharma
Chai Discovery Inc., a company that develops artificial intelligence models to predict interactions between biochemical molecules, today announced it has raised $400 million in Series C funding, nearly tripling its valuation to $3.8 billion.
Index Ventures led the round alongside Kleiner Perkins, Sequoia Capital and Dimension. New investors joining the investment included Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT & MSD, Sapphire Ventures, Avra Capital and other notable investors. Existing investors included Thrive Capital, OpenAI, Oak HC/FT, Menlo Ventures and General Catalyst, among others.
The round raises the company’s total funding to around $630 million to date, including $130 million at a $1.3 billion valuation in December.
Chai Discovery builds frontier AI models designed to accelerate drug discovery. They act by predicting and reprogramming molecular interactions, a necessary first step toward fully understanding how chemistry works for pharmaceutical and life sciences companies.
